Loading…
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-177M | $-191M | $-150M | -65.3% | -100.0% | - |
| 2024 | $0M | $-243M | $-258M | $-201M | -61.0% | -76.8% | - |
| 2023 | $0M | $-313M | $-327M | $-239M | -63.9% | -39.1% | - |
| 2022 | $0M | $-321M | $-340M | $-226M | -51.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0.16 | 0.10 | 0.02 | 0 |
| Operating Expense | 335.69 | 314.59 | 257.50 | 206.93 |
| Operating Income | -335.54 | -314.49 | -257.48 | -206.93 |
| EBITDA | -321.24 | -313.07 | -243.33 | -177.45 |
| EBIT | -335.54 | -327.26 | -256.97 | -189.81 |
| Pretax Income | -340.41 | -327.26 | -257.15 | -190.89 |
| Tax Provision | 0 | 0 | 0.44 | 0 |
| Net Income | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income Common Stockholders | -340.41 | -327.26 | -257.59 | -190.89 |
| Total Expenses | 335.69 | 314.59 | 257.50 | 206.93 |
| Interest Expense | 0 | 0 | 0.18 | 1.07 |
| Interest Income | 4.57 | 18.31 | 20.15 | 19.29 |
| Research And Development | 256.39 | 242.91 | 192.30 | 150.15 |
| Selling General And Administration | 79.31 | 71.67 | 65.20 | 56.78 |
| Normalized EBITDA | -321.24 | -299.82 | -227.61 | -175.07 |
| Normalized Income | -340.41 | -314.02 | -245.17 | -188.50 |
| Basic EPS | -2.32 | -2.09 | -1.32 | 0 |
| Diluted EPS | -2.32 | -2.09 | -1.32 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | -3.30 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0 |
| Total Unusual Items | 0 | -13.24 | -15.72 | -2.38 |
| Total Unusual Items Excluding Goodwill | 0 | -13.24 | -15.72 | -2.38 |
| Net Income From Continuing Operation Net Minority Interest | -340.41 | -327.26 | -257.59 | -190.89 |
| Reconciled Depreciation | 14.29 | 14.20 | 13.64 | 12.36 |
| Net Interest Income | 4.57 | 18.31 | 19.97 | 18.21 |
| Net Income From Continuing And Discontinued Operation | -340.41 | -327.26 | -257.59 | -190.89 |
| Total Operating Income As Reported | -335.54 | -327.74 | -273.20 | -209.31 |
| Diluted Average Shares | 143.15 | 156.93 | 194.81 | 0 |
| Basic Average Shares | 143.15 | 156.93 | 194.81 | 0 |
| Diluted NI Availto Com Stockholders | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income Including Noncontrolling Interests | -340.41 | -327.26 | -257.59 | -190.89 |
| Net Income Continuous Operations | -340.41 | -327.26 | -257.59 | -190.89 |
| Other Income Expense | -9.44 | -31.08 | -19.64 | -2.17 |
| Other Non Operating Income Expenses | -9.44 | -17.84 | -3.92 | 0.21 |
| Special Income Charges | 0 | -13.24 | -15.72 | -2.38 |
| Impairment Of Capital Assets | 0 | 13.24 | 15.72 | 2.38 |
| Net Non Operating Interest Income Expense | 4.57 | 18.31 | 19.97 | 18.21 |
| Interest Expense Non Operating | 0 | 0 | 0.18 | 1.07 |
| Interest Income Non Operating | 4.57 | 18.31 | 20.15 | 19.29 |
| General And Administrative Expense | 79.31 | 71.67 | 65.20 | 56.78 |
| Other Gand A | 79.31 | 71.67 | 65.20 | 56.78 |
| Operating Revenue | 0.16 | 0.10 | 0.02 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc.this co. | ALLO | $726M | - | 1.65 | -65.3% | -1.79 |
| BioAge Labs, Inc. | BIOA | $749M | - | 2.32 | -29.6% | -5.11 |
| Castle Biosciences, Inc. | CSTL | $734M | - | 1.53 | -5.1% | -224.72 |
| Absci Corporation | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| CBLL | CBLL | $729M | - |
| 4.65 |
| -34.4% |
| -10.30 |
| Gyre Therapeutics, Inc. | GYRE | $713M | 367.50 | 6.33 | 3.5% | 46.81 |
| Enhabit, Inc. | EHAB | $704M | - | 1.31 | -0.8% | 13.72 |
| Solid Biosciences Inc. | SLDB | $694M | - | 3.09 | -96.8% | -2.97 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $683M | 27.67 | -2.58 | -9.2% | 8.78 |
| Peer Median | - | 197.58 | 2.70 | -19.4% | -4.04 | |